Eurofins Genomics Opens New Seattle Laboratory for Express Oxford Nanopore Sequencing

News provided by

Jan 24, 2024, 10:00 ET

SEATTLE, Jan. 24, 2024 /PRNewswire/ -- Eurofins Genomics, a global leader in sequencing services, announces the opening of a new, certified sequencing lab in Bothell, Washington, serving the greater Seattle area. The facility leverages the Oxford Nanopore's sequencing platform and its local proximity to deliver results within 12 hours from sample pickup. The company has already lined up 30 partner labs in Seattle and conducting daily sample pickup and sequencing for the biotech hub.

The lab specializes in whole plasmid, amplicon, and bacterial genome sequencing, allowing researchers to unlock comprehensive insights into genetic structures in a fraction of the time of traditional next generation sequencing. This combination of novel technology and locality gives researchers and scientists a competitive edge in their genomic studies.

"Eurofins Genomics is proud to introduce our Seattle lab, where groundbreaking advancements in whole plasmid sequencing are set to transform the landscape of genetic research," said Sumit Gupta, President at Eurofins Genomics.

With its commitment to innovation, Eurofins Genomics' Seattle lab is poised to provide researchers greater access critical genomic information in record time and accelerate the pace of scientific discovery.

Media inquiries:

James Corne

[email protected]

+1 256-479-5809

Investor Relations

Eurofins Scientific Group

+ 32 2 766 1620

[email protected]

About Eurofins Genomics

Eurofins Genomics US is a leading provider of DNA synthesis, sequencing services, and gene synthesis. The company's strengths are its speed, quality, and commitment to customers. EurofinsGenomics.com.

About Eurofins Scientific

Eurofins Scientific, through its subsidiaries (hereinafter "Eurofins" or "the Group"), believes it is a global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric clinical diagnostic testing. With over 61,000 staff across a network of more than 900 independent companies in over 61 countries generally specialised by end client markets and operating more than 1000 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services.

SOURCE Eurofins Genomics